Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The GLP-1 drugs are also known as “incretin mimetics,” a hormone that stimulates insulin secretion in response to meals.
GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Patients with type-2 diabetes have diminished insulin release in response to meals, and it is speculated that they may have defects in the release or action of their incretin hormones.
Diabetes prevalence has increased rapidly in recent decades. It is estimated that in 2007, more than 100 million Asians were living with diabetes. Concurrently with the rise in the diabetic population, obesity is also rising sharply because of economic development, increasing sedentary lifestyles, and nutrition transition.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia, i.e., China and Japan.
Scope of the Report
The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region.
It is one of the most common chronic diseases in China and India. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Prevalence of Diabetes
China tops the global list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.
According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes.
WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.
The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, rising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.
Japan is Dominating the GLP-1 Market in the Asia-Pacific Region
Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.
In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.
By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.
Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.
Competitive Landscape
The Asia-Pacific GLP-1 market is consolidated, with four major manufacturers holding a presence in the region.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Sajjala Bio, Hyderabad, India, recently announced developments in a liraglutide biosimilar, and the company is aiming to launch the product by the end of 2019.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET INDICATORS
5.1 Type-1 Diabetes Population (2012-2024)
5.2 Type-2 Diabetes Population (2012-2024)
6 MARKET SEGMENTATION
6.1 By Drug
6.1.1 Exenatide
6.1.1.1 Byetta (Value and Volume, 2012-2024)
6.1.1.2 Bydureon (Value and Volume, 2012-2024)
6.1.2 Liraglutide
6.1.2.1 Victoza (Value and Volume, 2012-2024)
6.1.3 Lixisenatide
6.1.3.1 Lyxumia (Value and Volume, 2012-2024)
6.1.4 Dulaglutide
6.1.4.1 Trulicity (Value and Volume, 2012-2024)
6.2 Geography
6.2.1 Asia-Pacific
6.2.1.1 Japan (Value and Volume, 2012-2024)
6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.2 China (Value and Volume, 2012-2024)
6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.3 Australia (Value and Volume, 2012-2024)
6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.4 India (Value and Volume, 2012-2024)
6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.5 South Korea (Value and Volume, 2012-2024)
6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.6 Malaysia (Value and Volume, 2012-2024)
6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.7 Indonesia (Value and Volume, 2012-2024)
6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.8 Thailand (Value and Volume, 2012-2024)
6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.9 Philippines (Value and Volume, 2012-2024)
6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.10 Rest of Asia-Pacific (Value and Volume, 2012-2024)
6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Astra Zeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Astra Zeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume, 2012-2024)
Bydureon (Value and Volume, 2012-2024)
Liraglutide
Victoza (Value and Volume, 2012-2024)
Lixisenatide
Lyxumia (Value and Volume, 2012-2024)
Dulaglutide
Trulicity (Value and Volume, 2012-2024)
Geography
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Medical Alert System/Personal Emergency Response System Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 13-06-2019
Market Overview
The propelling factors for the growth of the medical alert system/personal emergency response system market include the increasing aging population, technological developments in healthcare wearables, increasing penetration of smartphones in healthcare and constant innovations in technology, and easy adaptability of PERS devices. Owing to the aforementioned factors, the market is expected to experience a boost during the forecast period.
With the rapid increase in the elderly population, there is a growing need for medical alert systems in the houses. Personal emergency response systems (PERS) are mainly for the older population and people with disabilities to easily call for help in an emergency. They are also widely adopted and used throughout most western countries. Therefore, with the help of medical alert systems, the elderly can age in the comfort of their own homes, and thus, this factor is likely to propel the growth of the overall market.
The current market is also growing due to the increasing adoption of smartphones. The global smartphone penetration is estimated at an all-time high, and thus, smartphones are crucial in one’s daily life, which is a major factor for the growth of the market.
The wearable health industry has also exploded in recent years, and thus this trend is expected to grow rapidly in the coming years. These wearables are used to monitor the health and well-being of people. In addition, there are technological advancements in wearables that may help the patients to adopt medical systems in the coming years.
Scope of the Report
As per the scope of the report, personal emergency response systems (PERS), also known as medical emergency response systems, allow users to call for help during an emergency by pushing a button. Therefore, due to the rapid increase in elderly population, there is a growing need for medical alert systems.
Key Market Trends
Mobile PERS Segment by Type is Expected to Grow the Fastest During the Forecast Period
Mobile PERS is found to be the largest segment as these units possess many advantages over traditional PERS units, which include tracking capabilities via a variety of technologies. In addition, they are also lightweight and durable. They are gaining popularity as they allow senior citizens to lead a more independent and healthy lifestyle.
The increasing demand for medical assistance, especially for the elderly, has also resulted in the increasing adoption of landline PERS, which is likely to result in the growth of the medical alert system market over the forecast period.
Asia-Pacific Holds the Fastest Growth in the Market and is Expected to Follow the Same Trend Over the Forecast Period
Asia-Pacific is estimated to be the fastest-growing region in the overall market over the forecast period, owing to the increasing geriatric population and increasing prevalence of chronic diseases. Also, the need for improved healthcare facilities and an increase in home-based health programs are expected to drive the market. Thus, increasing geriatric population and chronic diseases may lead to the growth of the medical alert system market.
The rising technological advancements, increasing awareness among the people, and increasing investments from foreign players are, therefore, expected to augment the growth of the medical alert system market in the future in this region.
Competitive Landscape
Key players are focusing on expanding their product portfolios to increase their market share. In addition, they are adopting strategies, such as acquisitions and collaborations. There are various companies in the medical alert system market, including ADT Corporation, Bay Alarm Medical, Philips Lifeline, Life Alert Emergency Response Inc., VRI Inc., and many others, which are leading players in the global market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Aging Population Across the World
4.2.2 Technological Developments in Healthcare Wearables
4.2.3 Increasing Penetration of Smartphones in Healthcare
4.2.4 Constant Innovations in Technology and Easy Adaptability of PERS Devices
4.3 Market Restraints
4.3.1 Overall Cost Associated with the System is High
4.3.2 Lack of Know-how Pertaining to the New Technology used in the PERS System
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Landline PERS
5.1.2 Mobile PERS
5.1.3 Other Types
5.2 By End User
5.2.1 Home-based Users
5.2.2 Senior Living Facilities
5.2.3 Assisted Living Facilities
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ADT Corporation
6.1.2 Bay Alarm Medical
6.1.3 Philips Lifeline (Koninklijke Philips N.V.)
6.1.4 Life Alert
6.1.5 VRI Inc.
6.1.6 Tunstall
6.1.7 Medical Guardian LLC
6.1.8 Alertone Services LLC
6.1.9 Greatcall
6.1.10 Rescue Alert
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Landline PERS
Mobile PERS
Other Types
By End User
Home-based Users
Senior Living Facilities
Assisted Living Facilities
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
3D Cell Culture Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 13-06-2019
Market Overview
The 3D cell culture market is witnessing a stable growth due to the factors, like huge investments by life science companies for R&D, development of automated large-scale cell culture systems, and rising need for organ transplantation. Lack of experienced and skilled professionals and budget restriction for small and medium-sized laboratories are factors constraining the growth of the 3D cell culture market. However, increasing focus on regenerative medicine and stem cell is acting as an opportunity in the future. The scaffold-based segment holds the largest market share in the global market. The use of hydrogels in the scaffold-based 3D cell culture is the key factor driving the scaffold-based segment, as they can be derived naturally from protein and ECM components (laminin, fibrin, hyaluronic acid, chitosan, etc.). These gels are also biocompatible.
Scope of the Report
This report analyzes and discusses the 3D cell culture market. The market has been segmented on the basis of technology, application, end user, and geography. Based on technology, the market has been segmented into extracellular matrices (scaffolds), bioreactors, gels, scaffold-free platforms, microchips, and other technologies. The market, based on application, has been divided into research, drug discovery, tissue engineering, clinical applications, stem cell biology, and other applications. Based on end user, the market has been segregated into research laboratories and institutes, biotechnology and pharmaceutical industries, hospitals and diagnostic centers, and others end users.
Key Market Trends
Drug Discovery Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period
Conventionally, drug discovery has been carried out using animal models. However, with the explosion of drug molecules synthesized/discovered in the past two decades, there has been a growth in high-throughput screening. Consequently, drug discovery has become a process that was time-resource intensive. Additionally, animal testing is subject to ethical controversies. Consequently, the demand for alternative methods for drug testing and drug discovery processes has gained momentum.
A specific application of 3D cell culture in drug discovery is organ-on-chips. These systems are being extensively employed by cancer therapeutic manufacturers for improving the benefit-risk balance by targeting precisely a particular cell type, a defined biomechanism, or a precise receptor. The current up-trend in cancer therapeutics’ research is likely to further spur the application of 3D cell cultures in drug discovery. Over the forecast period, much novel cancer therapeutics are expected to receive market approval, which is likely to, in turn, drive the growth of the 3D cell culture market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall 3D cell culture market with the United States accounting as the major contributor to the market. The United States is focusing more on R&D and is currently spending a lot on it. This has resulted in increasing technological advancements in the country. Many American applicants feature among the main patent applicants for the 3D cell culture domain. American applicants tend to develop their technologies in the United States, as well as in Asia. In 2016, an international collaboration between the United States, the United Kingdom, and the Netherlands, cancer-research heavy-weights, aimed to grow 1,000 new cell lines for scientists to study. The project is also expected to use cutting-edge techniques to generate its models, which will include 3D cultures called organoids, and cells that have been reprogrammed to grow indefinitely in culture. ICTDCCS 2018, 20th International Conference on 3D Cell Culture Systems, was held in Boston (the United States) on April 23-24, 2018. These factors have augmented the US 3D cell culture market and it is expected to further increase in the future.
Competitive Landscape
The 3D cell culture market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as 3D Biomatrix, Reinnervate Ltd, 3D Biotek LLC, Becton, Dickinson and Company, and Sigma Aldrich Corporation, is in turn, increasing the overall competitive rivalry in the market. Product advancements and improvement in the 3D cell culture technology by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Huge R&D Investment by Life Science Companies
4.3.2 Development of Automated Large-scale Cell Culture Systems
4.3.3 Rising Need for Organ Transplantation
4.3.4 Use of 3D Cell Culture Models as Alternative Tools for In Vivo Testing
4.3.5 Increasing Focus on Regenerative Medicine
4.4 Market Restraints
4.4.1 Lack of Experienced and Skilled Professionals
4.4.2 Budget Restriction for Small- and Medium-sized Laboratories
4.4.3 Lack of Consistency in 3D Cell Culture Products
4.4.4 Stringent Process Controls for Advanced Handling Capabilities
4.5 Industry Attractiveness- Porter’s Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Extracellular Matrices (Scafffolds)
5.1.2 Bioreactors
5.1.3 Gels
5.1.4 Scaffold-free Platforms
5.1.5 Microchips
5.1.6 Other Technologies
5.2 By Application
5.2.1 Research
5.2.2 Drug Discovery
5.2.3 Tissue Engineering
5.2.4 Clinical Applications
5.2.5 Stem Cell Biology
5.2.6 Other Applications
5.3 By End User
5.3.1 Research Laboratories and Institutes
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Hospitals and Diagnostic Centers
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 UK
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3D Biotek LLC
6.1.2 Becton Dickinson and Company
6.1.3 Sigma Aldrich Corporation
6.1.4 Corning Incorporated
6.1.5 Thermo Fisher Scientific
6.1.6 Global Cell Solutions Inc.
6.1.7 Nanofiber Solutions Incorporation
6.1.8 Insphero AG
6.1.9 Lonza Group
6.1.10 Nano 3D Biosciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Extracellular Matrices (Scafffolds)
Bioreactors
Gels
Scaffold-free Platforms
Microchips
Other Technologies
By Application
Research
Drug Discovery
Tissue Engineering
Clinical Applications
Stem Cell Biology
Other Applications
By End User
Research Laboratories and Institutes
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Other End Users
Geography
North America
US
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Tele Intensive Care Unit Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 13-06-2019
Market Overview
The tele-intensive care unit market was valued at USD 2,441.38 million in 2018, and it is estimated to be valued at USD 6,715.61 million by 2024, while witnessing a CAGR of 18.37% during the forecast period of 2019-2024. Factors that are responsible for the growth of the market include, rising geriatric population across the world and increasing demand for remote patient monitoring in developing regions.
With the increasing geriatric population and prevalence of chronic diseases, there is a growing need to find new ways of improving patient outcomes, increasing access to care, and reducing the cost of medical care. Using remote patient monitoring, which utilizes devices to remotely collect and direct information to a remote diagnostic testing facility for interpretation, the healthcare providers, insurance payers, and the various governments are seeking to alter the way in which care is being delivered, thus reducing the cost of care at the same time. As the aging population creates an increase in health-related issues, especially cardiovascular and neurological diseases, the hospitalization of the patients is also expected to rise. This hospitalization is likely to lead to some sort of surgeries that require intensive care, and this is expected to drive the tele-intensive care unit market.
Scope of the Report
The tele-intensive care unit (ICU) is like the second set of eyes that provides additional clinical support and surveillance. Collaborating tele ICU with the bedside team can provide support care for the patient without any distraction, and can deliver in timely interventions when minutes may make a huge difference. The major purpose of the tele ICU system is not to replace the bedside clinicians or bedside care, but to provide improved safety through redundancy and enhance outcomes through standardization.
Key Market Trends
Therapeutic Devices Sub-segment is Expected to Hold the Largest Market Share in the Hardware Segment
In the hardware segment of the tele-intensive care unit market, the therapeutic devices sub-segment is expected to have largest market share, and is expected to witness a CAGR of 18.51% over the forecast period.
In the past decade, there were several studies being conducted by engineers and clinicians to apply robotic devices in multiple indications of heart and brain, such as stroke therapy. The therapeutic devices are highly useful in the decentralized tele ICU. A large number of nursing activities are increasing their dependency and providing better patient management through therapeutic devices, even when they are disengaged from therapeutic interactions.
The therapeutics devices have achieved success in transferring the neurological/cancer examinations, diagnosis, and consultations across a range of distances in several developed countries. Therapeutic devices under tele ICU are aiding its importance, with the potential to help providers and caregivers to improve the post-acute care, specifically for patients leaving the ICUs. Thus, over the forecast period, the awareness about these devices is expected to significantly improve across the emerging markets.
North America Dominates the Market and is Expected to do Same during the Forecast Period
North America currently dominates the tele-intensive care unit market and is expected to continue its stronghold for a few more years. The emergence of novel technologies, along with their adoption, is helping the United States to grow in the healthcare sector. Rising healthcare expenditure is the prime factor responsible for the growth of this sector. The rapid increase in the older population and rising life expectancy are propelling the growth of the tele ICU market in the country. Due to the rising older population, an increasing number of emergency cases are coming to ICU departments in hospitals, which in turn, is creating the need for improved ICU care. Therefore, the market for tele ICUs is expected to experience growth in the North American region over the forecast period.
Competitive Landscape
The tele-intensive care unit market is highly competitive and consists of several major players. In terms of market share, there is moderate consolidation in the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Banner Health, INTeLeICU, Philips (VISICU), InTouch Technologies Inc., and Inova, hold the substantial market share in the tele-intensive care unit market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population
4.2.2 Increasing Demand for Remote Patient Monitoring
4.3 Market Restraints
4.3.1 High Cost of Treatment and Expensive Set Up
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Component
5.1.1 Hardware
5.1.1.1 Therapeutic Devices
5.1.1.2 Communication Lines
5.1.1.3 Computer Systems
5.1.1.4 Physiological Monitors
5.1.1.5 Display Panels
5.1.1.6 Video Feed
5.1.1.7 Other Hardware
5.1.2 Software and Services
5.2 By Type of Management
5.2.1 Intensivist
5.2.2 Open
5.2.3 Co-managed
5.2.4 Open with Consultant
5.2.5 Other Types of Management
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Advanced ICU Care
6.1.2 Banner Health
6.1.3 iMDsoft
6.1.4 INTeLeICU
6.1.5 InTouch Technologies Inc.
6.1.6 Koninklijke Philips NV
6.1.7 SOC Telemed
6.1.8 UPMC Italy
6.1.9 Apollo Telehealth Services
6.1.10 Advanced ICU Care
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Component
Hardware
Therapeutic Devices
Communication Lines
Computer Systems
Physiological Monitors
Display Panels
Video Feed
Other Hardware
Software and Services
By Type of Management
Intensivist
Open
Co-managed
Open with Consultant
Other Types of Management
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Stem Cell Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 13-06-2019
Market Overview
The stem cell market is experiencing growth, owing to the increasing number of clinical trials around the world. North America, especially the United States, dominated the number of trials undergoing in stem cell therapies. The United States dominates the market in both the products and banking services segments, holding around 77.4% of the total North American market. However, Asia-Pacific is growing at the highest growth rate. Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest growth rate, due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.
Stem cells banking is gaining importance with the support of government initiatives. The number of stem cell banks is increasing in developing countries, which is aiding the growth of the market. Also, increasing awareness about stem cell storage among the people has positively affected the market. Currently, the market is not well established in many therapeutic areas and has shown nascent success in history. However, it holds great potential in both the diagnosis and therapeutic fields.
Scope of the Report
The scope of this market is limited to tracking the stem cell market. As per the scope of this report, stem cells are biological cells that can differentiate into other types of cells. Also, various types of stem cells are used for therapeutic purposes.
Key Market Trends
Oncology Disorders Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
Cancer has a major impact on society in the United States and across the world. As per the estimation of National Cancer Institute, in 2018, 1,735,350 new cases of cancer were anticipated to get diagnosed in the United States, and 609,640 deaths were expected from the disease. This increasing medical burden is due to population growth. Bone marrow transplant or stem cell transplant is a treatment for some types of cancers, like leukemia, multiple myeloma, multiple myeloma, neuroblastoma, or some types of lymphoma.
Embryonic stem cells (ESC) are the major source of stem cells for therapeutic purposes, due to their higher totipotency and indefinite lifespan, as compared to adult stem cells with lower totipotency and restricted lifespan. However, the use of ESCs for research and therapeutic purposes is restricted and prohibited in many countries throughout the world, due to some ethical constraints. Scientists from the University of California, Irvine, created the stem cell-based approach to kill cancerous tissue while preventing some toxic side effects of chemotherapy by treating the disease in a more localized way.
Although the market shows positive growth, due to the growing focus of stem cell-based research that can further strengthen the clinical application, its expensive nature for stem cell therapy may still hamper its growth.
North America Captured The Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall stem cell market with the United States contributing to the largest share in the market. In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell-based therapy in patients with chronic spinal cord injury. Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.
Competitive Landscape
The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific, Qiagen NV, Sigma Aldrich (A Subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in stem cell technology by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness about Umbilical Stem Cell
4.2.2 Increase in the Approval for Clinical Trials in Stem Cell Research
4.2.3 Growing Demand for Regenerative Treatment Option
4.2.4 Rising R&D Initiatives to Develop Therapeutic Options for Chronic Diseases
4.3 Market Restraints
4.3.1 Expensive Procedures
4.3.2 Regulatory Complications
4.3.3 Ethical and Moral Framework
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Adult Stem Cell
5.1.2 Human Embryonic Cell
5.1.3 Pluripotent Stem Cell
5.1.4 Other Product Types
5.2 By Therapeutic Application
5.2.1 Neurological Disorders
5.2.2 Orthopedic Treatments
5.2.3 Oncology Disorders
5.2.4 Diabetes
5.2.5 Injuries and Wounds
5.2.6 Cardiovascular Disorders
5.2.7 Other Therapeutic Applications
5.3 By Treatment Type
5.3.1 Allogeneic Stem Cell Therapy
5.3.2 Auto logic Stem Cell Therapy
5.3.3 Syngeneic Stem Cell Therapy
5.4 By Banking Service and Technology
5.4.1 Stem Cell Acquisition and Testing
5.4.2 Cell Production
5.4.3 Expansion
5.4.4 Sub-culture
5.4.5 Cryopreservation
5.5 By Type of Banking
5.5.1 Public
5.5.2 Private
5.6 Geography
5.6.1 North America
5.6.1.1 US
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 UK
5.6.2.2 Germany
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East & Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East & Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Osiris Therapeutics Inc.
6.1.2 Pluristem Therapeutics Inc.
6.1.3 Thermo Fisher Scientific
6.1.4 Qiagen NV
6.1.5 Sigma Aldrich Corporation
6.1.6 Becton, Dickinson and Company
6.1.7 Stem Cell Technologies Inc.
6.1.8 AllCells LLC
6.1.9 Miltenyi Biotec
6.1.10 International Stem Cell Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Adult Stem Cell
Human Embryonic Cell
Pluripotent Stem Cell
Other Product Types
By Therapeutic Application
Neurological Disorders
Orthopedic Treatments
Oncology Disorders
Diabetes
Injuries and Wounds
Cardiovascular Disorders
Other Therapeutic Applications
By Treatment Type
Allogeneic Stem Cell Therapy
Auto logic Stem Cell Therapy
Syngeneic Stem Cell Therapy
By Banking Service and Technology
Stem Cell Acquisition and Testing
Cell Production
Expansion
Sub-culture
Cryopreservation
By Type of Banking
Public
Private
Geography
North America
US
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
North America Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
GLP-1 drugs are also known as “Incretin mimetics,” a hormone that stimulates insulin secretion in response to meals.
The GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Patients with type-2 diabetes have diminished insulin release in response to meals and it is speculated that they may have defects in the release or action of their incretin hormones.
Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like increasing median age and health factors, including increasing obesity and inactivity levels among people.
GLP-1 agonist market holds 17.2% of the total North American diabetes drug market in 2017 which is also expected to grow with the CAGR of 6.53% in the forecast period (2019-2024).
Scope of the Report
The report is focussed on GLP-1 drugs for type-2 diabetes mellitus. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Growing Type-2 Diabetes Population in North America
It is estimated that within the region, the age-adjusted prevalence of diabetes for the United States is around 9.2%, and is around 7.9% for Canada and 12.6% for Mexico.
The economic impact is also significant. Healthcare spending due to diabetes was estimated to be USD 426.8 million in 2017, the highest of all IDF regions.
The North American region suffers from a high burden of diabetes, and its subsequent adverse health and economic consequences. The disease should be viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in Canada.
The US to Dominate the Market during the Forecast Period
Among the countries in North America, the United States dominates the market, owing to the high prevalence of diabetes and obesity in the region, because of a sedentary lifestyle.
The cost factor is the primary concern in the United States, where almost 50% of the market share for manufacturers is from the United States itself.
In 2017, the US GLP-1 market share in the diabetes segment was reported to be 96%.
Competitive Landscape
The North America GLP-1 market is consolidated, with four major manufacturers holding a presence in the North American region.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Teva confirmed generic Victoza and announced that it had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market the generic version of Novo Nordisk’s Victoza® (liraglutide) injection, in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 Introduction
1.1 Scope of Study
1.2 Market Definition
1.3 Executive Summary
2 Research Methodology
2.1 Study Deliverables
2.2 Study Assumptions
2.3 Research Phases
3 Market Insights
3.1 Current Market Scenario
3.2 Technology Trends
3.3 Industry Attractiveness – Porter’s Five Forces Analysis
3.3.1 Bargaining Power of the Suppliers
3.3.2 Bargaining Power of the Consumers
3.3.3 Threat of New Entrants
3.3.4 Threat of Substitute Products and Services
3.3.5 Competitive Rivalry within the Industry
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
5 Market Indicators
5.1 Type-1 Diabetes Population
5.2 Type-2 Diabetes Population
6 Market Segmentation and Analysis
6.1 By Drug (Value and Volume, 2012-2024)
6.1.1 Exenatide
6.1.1.1 Byetta
6.1.1.2 Bydureon
6.1.2 Liraglutide
6.1.2.1 Victoza
6.1.3 Lixisenatide
6.1.3.1 Lyxumia
6.1.4 Dulaglutide
6.1.4.1 Trulicity
7 Geography
7.1 North America (Value and Volume, 2012-2024)
7.1.1 United States
7.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
7.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
7.1.2 Canada
7.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
7.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
7.1.3 Rest of North America
7.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
7.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
8 Competitive Landscape
8.1 Company Profiles
8.1.1 Novo Nordisk
8.1.2 AstraZeneca
8.1.3 Eli Lilly and Company
8.1.4 Sanofi
8.2 Market Share Analysis
8.2.1 Novo Nordisk
8.2.2 AstraZeneca
8.2.3 Eli Lilly and Company
8.2.4 Sanofi
9 FUTURE OF THE MARKET
10 MARKET OPPORTUNITIES AND FUTURE TRENDS
Market Segmentation and Analysis
By Drug (Value and Volume, 2012-2024)
Exenatide
Byetta
Bydureon
Liraglutide
Victoza
Lixisenatide
Lyxumia
Dulaglutide
Trulicity
Geography
North America (Value and Volume, 2012-2024)
United States
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Canada
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of North America
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)